[go: up one dir, main page]

CY2020033I2 - Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης - Google Patents

Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης

Info

Publication number
CY2020033I2
CY2020033I2 CY2020033C CY2020033C CY2020033I2 CY 2020033 I2 CY2020033 I2 CY 2020033I2 CY 2020033 C CY2020033 C CY 2020033C CY 2020033 C CY2020033 C CY 2020033C CY 2020033 I2 CY2020033 I2 CY 2020033I2
Authority
CY
Cyprus
Prior art keywords
sphygosine
phosphorate
receptors
novel regulators
regulators
Prior art date
Application number
CY2020033C
Other languages
English (en)
Other versions
CY2020033I1 (el
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of CY2020033I1 publication Critical patent/CY2020033I1/el
Publication of CY2020033I2 publication Critical patent/CY2020033I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY2020033C 2008-05-14 2020-10-02 Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης CY2020033I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12760308P 2008-05-14 2008-05-14
PCT/US2009/003014 WO2009151529A1 (en) 2008-05-14 2009-05-14 Novel modulators of sphingosine phosphate receptors
US12/465,767 US8796318B2 (en) 2008-05-14 2009-05-14 Modulators of sphingosine phosphate receptors
EP09762826.7A EP2291080B1 (en) 2008-05-14 2009-05-14 Novel modulators of sphingosine phosphate receptors

Publications (2)

Publication Number Publication Date
CY2020033I1 CY2020033I1 (el) 2020-11-25
CY2020033I2 true CY2020033I2 (el) 2021-01-27

Family

ID=41416994

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20201100862T CY1123338T1 (el) 2008-05-14 2020-09-11 Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης
CY2020033C CY2020033I2 (el) 2008-05-14 2020-10-02 Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20201100862T CY1123338T1 (el) 2008-05-14 2020-09-11 Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης

Country Status (20)

Country Link
US (8) US8796318B2 (el)
EP (3) EP2291080B1 (el)
JP (2) JP5837417B2 (el)
AU (2) AU2009258242B2 (el)
CY (2) CY1123338T1 (el)
DK (1) DK2291080T3 (el)
EA (1) EA021672B1 (el)
ES (2) ES2549761T3 (el)
FI (2) FI2291080T5 (el)
HR (1) HRP20150982T1 (el)
HU (2) HUE025984T2 (el)
LT (1) LTC2291080I2 (el)
MY (2) MY156381A (el)
NL (1) NL301065I2 (el)
NO (1) NO2020034I1 (el)
NZ (1) NZ589617A (el)
PL (2) PL2291080T3 (el)
PT (2) PT2291080E (el)
SI (1) SI2291080T1 (el)
WO (1) WO2009151529A1 (el)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2069336T1 (sl) 2006-09-07 2013-03-29 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot imunomodulirna sredstva
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
MX2010001881A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores del receptor s1p1/edg1.
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
CN101896482B (zh) 2007-12-10 2013-01-09 埃科特莱茵药品有限公司 作为s1p1/edg1激动剂的噻吩衍生物
RU2010140847A (ru) 2008-03-07 2012-04-20 Актелион Фармасьютиклз Лтд (Ch) Новые производные аминометилбензола
MY156381A (en) 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
MX339144B (es) 2008-06-09 2016-05-13 Univ Muenchen Ludwig Maximilians Nuevas drogas para inhibir la agregacion de proteinas involucradas en enfermedades relacionadas con la agregacion de proteinas y/o enfermedades neurodegenerativas.
UY31922A (es) * 2008-06-20 2010-01-05 Glaxo Group Ltd Compuestos
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
KR101800595B1 (ko) 2008-08-27 2017-11-22 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체
CN102361867A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
JP2012515788A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
MY153617A (en) 2009-07-16 2015-02-27 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
AU2015202660B2 (en) * 2009-11-13 2016-10-27 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MY161854A (en) * 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EA025672B1 (ru) * 2009-11-13 2017-01-30 Рецептос Ллк Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
RS57070B1 (sr) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2390252A1 (en) * 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
MX350009B (es) 2011-01-19 2017-08-23 Idorsia Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo.
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
CN102718726A (zh) * 2011-03-31 2012-10-10 上海铂力生物科技有限公司 作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
ES2758841T3 (es) * 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
DK2958913T3 (en) 2013-02-20 2018-11-05 Lg Chemical Ltd SPHINGOSIN-1 PHOSPHATRECEPTOR AGONISTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS AN ACTIVE AGENT
EA029309B1 (ru) * 2013-03-15 2018-03-30 Идорсиа Фармасьютиклз Лтд Производные пиридин-4-ила в качестве агонистов s1p/edg1
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
MX2017000184A (es) * 2014-06-26 2017-09-15 Univ Monash Agentes de interaccion enzimatica.
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
AU2016246398A1 (en) 2015-04-06 2017-10-26 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
EP3470400B1 (en) 2016-06-14 2025-04-02 Receptos LLC Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
CN109563059A (zh) 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
US10275027B2 (en) 2017-01-23 2019-04-30 Naqi Logics, Llc Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
CN110944982A (zh) 2017-08-31 2020-03-31 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020152718A1 (en) 2019-01-25 2020-07-30 Mylan Laboratories Limited Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
EP3959204A4 (en) * 2019-04-26 2022-12-28 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
WO2021026479A1 (en) * 2019-08-07 2021-02-11 Stamford, Andrew Small molecule inhibitors of s1p2 receptor and uses thereof
CA3165424A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4126827B1 (en) * 2020-03-27 2024-11-20 Receptos LLC Sphingosine 1 phosphate receptor modulators
EP4126829A1 (en) * 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
US12428386B2 (en) 2020-03-27 2025-09-30 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021207051A1 (en) * 2020-04-06 2021-10-14 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
US20230233532A1 (en) * 2020-06-26 2023-07-27 The Penn State Research Foundation Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
US20230265082A1 (en) * 2020-08-10 2023-08-24 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
CN121194965A (zh) 2023-05-31 2025-12-23 奎米卡新特缇卡股份有限公司 盐酸奥扎莫德的无定形形式和晶型
CN119320366B (zh) * 2023-07-17 2025-11-18 中国医学科学院药物研究所 取代萘甲基噁二唑-苯胺类化合物及其用途
US11905265B1 (en) * 2023-10-13 2024-02-20 King Faisal University 3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
NZ505599A (en) * 1998-01-23 2003-06-30 Sankyo Co Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
CA2509218C (en) * 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
WO2004096220A1 (en) 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2005058845A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PT1650186E (pt) * 2004-10-22 2008-09-16 Bioprojet Soc Civ Novos derivados de ácidos dicarboxílicos
CA2600008A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
AU2006328602B2 (en) * 2005-12-23 2012-05-31 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
PT2003132E (pt) * 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2664268A1 (en) 2006-09-29 2008-04-03 Novartis Ag Diaryl oxadiazol derivatives
CA2669104A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
US20090188269A1 (en) 2008-01-25 2009-07-30 Henkel Corporation High pressure connection systems and methods for their manufacture
LT2913326T (lt) 2008-05-14 2020-09-10 The Scripps Research Institute Nauji sfingozino fosfatų receptorių moduliatoriai
MY156381A (en) * 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors

Also Published As

Publication number Publication date
US20190084947A1 (en) 2019-03-21
WO2009151529A1 (en) 2009-12-17
EP2913326B1 (en) 2020-07-15
LTPA2020529I1 (lt) 2020-10-26
FI2291080T5 (fi) 2023-11-06
EP2291080B1 (en) 2015-08-19
HUS2000038I1 (hu) 2020-10-28
CY2020033I1 (el) 2020-11-25
MY172105A (en) 2019-11-14
PL2291080T3 (pl) 2015-12-31
PT2913326T (pt) 2020-08-24
EP2291080A4 (en) 2013-09-11
AU2015213309A1 (en) 2015-09-03
NL301065I1 (el) 2020-09-30
EA201001785A1 (ru) 2011-10-31
JP2011523412A (ja) 2011-08-11
US20180009770A1 (en) 2018-01-11
EP2291080A1 (en) 2011-03-09
JP2016041736A (ja) 2016-03-31
MY156381A (en) 2016-02-15
NO2020034I1 (no) 2020-09-29
US8530503B2 (en) 2013-09-10
LTC2291080I2 (lt) 2021-09-10
FIC20200037I1 (fi) 2020-09-24
SI2291080T1 (sl) 2015-11-30
NL301065I2 (nl) 2020-10-28
WO2009151529A9 (en) 2010-04-08
DK2291080T3 (en) 2015-12-07
US20120329838A1 (en) 2012-12-27
CY1123338T1 (el) 2020-11-25
HUE025984T2 (hu) 2016-05-30
AU2009258242A1 (en) 2009-12-17
US8481573B2 (en) 2013-07-09
US8466183B2 (en) 2013-06-18
JP5837417B2 (ja) 2015-12-24
ES2549761T3 (es) 2015-11-02
AU2009258242B2 (en) 2015-07-16
US20150057307A1 (en) 2015-02-26
US10544136B2 (en) 2020-01-28
HRP20150982T1 (hr) 2015-10-23
AU2015213309B2 (en) 2016-10-13
PT2291080E (pt) 2015-10-30
US20120329839A1 (en) 2012-12-27
US20170050941A1 (en) 2017-02-23
EP3782991A1 (en) 2021-02-24
FI2291080T3 (el) 2015-10-15
EA021672B1 (ru) 2015-08-31
ES2813368T3 (es) 2021-03-23
US9382217B2 (en) 2016-07-05
US20120329840A1 (en) 2012-12-27
US9975863B2 (en) 2018-05-22
US8796318B2 (en) 2014-08-05
NZ589617A (en) 2012-06-29
EP2913326A1 (en) 2015-09-02
PL2913326T3 (pl) 2020-11-16
US20100010001A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CY2020033I2 (el) Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης
SMT201600222B (it) Formulazione di anticorpi
EP2590647A4 (en) PRO-NEUROGENIC COMPOUNDS
BR112012006686A2 (pt) composto amida substituído
EP2510089A4 (en) SYNTHESIS OF PRAZOL COMPOUNDS
DK2271219T3 (da) Anvendelse af dithiin-tetracarboximider til bekæmpelse af fytopatogene svampe
EP2648516A4 (en) SUBSTITUTED PYRIDINONE PYRIDINYL COMPOUNDS
IL225867B (en) Coelenterazine substrates
BR112013009935C8 (pt) compostos
SMT201400023B (it) Analoghi di buprenorfina
DE112009004703A5 (de) Schnappbefestigung
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
EP2620724A4 (en) EXPANSION VALVE
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
BR112014003878A2 (pt) síntese de r-bifenilalaninol
EP2399504A4 (en) DEVICE FOR INTRODUCING ENDOSCOPE
CO6801726A2 (es) Compuestos
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
EP2707101A4 (en) Proteostasis-REGULATORS
DE112010004699A5 (de) Schnappbefestigung
DK2649070T3 (da) Triazolpyridinforbindelser
EP2691361A4 (en) SYNTHESIS OF DIAZIDEN
EP2609107C0 (en) PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES